Record 01 Week of 5 October 2026 · REGULATION Six peptides recommended for the 503A bulks list · REGULATION From Category 2 to review: how twelve peptides came off the restricted list · REGULATION FDA proposes to end 503B compounding of semaglutide, tirzepatide and liraglutide · TRIALS Retatrutide: four Phase 3 readouts in 2026 · TRIALS Orforglipron approved; the oral GLP-1 question · PAPERS GLP-1 drugs recruit hunger neurons to sustain fat loss, Yale study finds · PAPERS A peptide–drug conjugate that hits five targets, in mice · PAPERS What GLP-1 users do differently: activity, bone and persistence · EVIDENCE BPC-157: what the human record contains · PUBLIC AND POLICY A public-health school explains the peptides in the feed · PUBLIC AND POLICY The gray market and the state patchwork · INDUSTRY Who makes peptides: capacity and ownership moves · Record 01 Week of 5 October 2026 · REGULATION Six peptides recommended for the 503A bulks list · REGULATION From Category 2 to review: how twelve peptides came off the restricted list · REGULATION FDA proposes to end 503B compounding of semaglutide, tirzepatide and liraglutide · TRIALS Retatrutide: four Phase 3 readouts in 2026 · TRIALS Orforglipron approved; the oral GLP-1 question · PAPERS GLP-1 drugs recruit hunger neurons to sustain fat loss, Yale study finds · PAPERS A peptide–drug conjugate that hits five targets, in mice · PAPERS What GLP-1 users do differently: activity, bone and persistence · EVIDENCE BPC-157: what the human record contains · PUBLIC AND POLICY A public-health school explains the peptides in the feed · PUBLIC AND POLICY The gray market and the state patchwork · INDUSTRY Who makes peptides: capacity and ownership moves ·

NEWS BRIEF PUBLIC Regulation and policy

A public-health school explains the peptides in the feed

Harvard's Chan School names the compounds influencers promote and sets out its concerns.

Published 5 Oct 2026 Event 1 Oct 2026 Sources 1 TYPE · INSTITUTIONAL EXPLAINERAUDIENCE · GENERAL PUBLICPUBLISHED · 1 OCT 2026

On 1 October 2026 the Harvard T.H. Chan School of Public Health published a question-and-answer piece on synthetic peptides in social media and the news. It names BPC-157 and TB-500 (promoted together as a recovery pairing), MOTS-c, CJC-1295 and ipamorelin as compounds pushed by influencers for workout recovery, injury healing and performance. [1]

The piece frames the compounds as largely untested in humans and raises concerns about sourcing and purity. It is an institutional explainer rather than a study, and is filed here because it marks the subject reaching a general audience from a public-health institution. [1]

SOURCES

Harvard T.H. Chan School of Public Health. Peptides are all over social media and the news. Here's what to know about them. 1 Oct 2026. Institutional explainer. https://hsph.harvard.edu/news/peptides-are-all-over-social-media-and-the-news-heres-what-to-know-about-them/

CHANGELOG · 5 Oct 2026 FIRST PUBLISHED · CORRECTIONS ARE ADDED HERE, NEVER HIDDEN